Gsk (GSK) Other financing activities (2009 - 2026)

Gsk (GSK) has 18 years of Other financing activities data on file, last reported at $2.1 billion in Q3 2026.

• For the quarter ending Q3 2026, Other financing activities changed N/A year-over-year to $2.1 billion; the trailing twelve-month figure through Sep 2026 stood at $4.4 billion (changed N/A YoY), and the FY2024 full-year result was $11.5 million, up 32.13% from the prior year.
• Other financing activities was $2.1 billion for Q3 2026 at Gsk, up from $2.7 million in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $2.1 billion in Q1 2026 to a low of -$36.5 million in Q1 2025.
• A 5-year average of $406.8 million and a median of $10.4 million in 2024 frame the typical range for Other financing activities.
• The largest YoY upside for Other financing activities was 12232.65% in 2025 against a maximum downside of 175.77% in 2025.
• Gsk's Other financing activities stood at $10.7 million in 2022, then dropped by 20.74% to $8.5 million in 2023, then tumbled by 84.92% to $1.3 million in 2024, then jumped by 12232.65% to $158.3 million in 2025, then surged by 1246.97% to $2.1 billion in 2026.
• Per Business Quant data, the three most recent Other financing activities figures were $2.1 billion in Q3 2026, $2.7 million in Q2 2026, and $2.1 billion in Q1 2026.